Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations

ROS proto-oncogene 1 (ROS1) rearrangements are reported in about 1–2% of non-squamous non-small-cell lung cancer (NSCLC). After efficacy of crizotinib was demonstrated, identification of ROS1 translocations in advanced disease became fundamental to give patients the chance of specific and effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Guaitoli, Giorgia, Bertolini, Federica, Bettelli, Stefania, Manfredini, Samantha, Maur, Michela, Trudu, Lucia, Aramini, Beatrice, Masciale, Valentina, Grisendi, Giulia, Dominici, Massimo, Barbieri, Fausto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657497/
https://www.ncbi.nlm.nih.gov/pubmed/34884672
http://dx.doi.org/10.3390/ijms222312867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657497/
https://www.ncbi.nlm.nih.gov/pubmed/34884672
http://dx.doi.org/10.3390/ijms222312867

Ejemplares similares